Basic Study

Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer

Renate S Olsen, Johnny Nijm, Roland E Andersson, Jan Dimberg, Dick Wågsäter

AIM

To investigate association of circulating inflammatory factors at the time of colorectal cancer (CRC) surgery with survival.

METHODS

Plasma levels from 174 CRC patients (69 females and 105 men), with median age 70 years (range 29-90), localized in the colon (n = 105) or rectum (n = 69), with stage I (n = 24), stage II (n = 54), stage III (n = 67) and stage IV (n = 29) were measured using commercially available Bio-Plex Pro™ Human Chemokine...
Panel 40-Plex, including 40 different chemokines, cytokines and interleukins. The prognostic association of each inflammatory factor was analysed as CRC-specific and total mortality.

RESULTS
Out of 174 patients, 66 died during the follow-up, 40 because of CRC specific mortality. High tertile levels of 8 factors were significantly associated with increased CRC-specific mortality, of which CCL1, CCL20, CCL24, CX3CL1, IL-4 and TNF-α remained significant in a multivariate Cox regression analysis. High tertile levels of 14 factors were associated with increased total mortality, of which CCL1, CCL15, CCL20, CX3CL1, CXCL13, IFN-γ, IL-2, IL-4 and IL-10 remained significant after adjustment for clinical covariates. For most of the inflammatory factors the association between higher tertile levels and an increased mortality in general appeared two years after surgery. High tertile levels of TNF-α and CCL24 were exclusively associated with CRC-specific mortality. The distribution of these factors were not associated with TNM stage with exception for CCL20.

CONCLUSION
High plasma levels of inflammatory factors are associated with increased risk of mortality among CRC patients and could be potential biomarkers for revealing prognosis.

Key words: Colorectal cancer; Inflammation; Cytokines; Plasma; Prognosis; Mortality

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Plasma levels of 40 different cytokines, chemokines and interleukins were analyzed in colorectal cancer (CRC) patients of which high tertile levels of nine factors were associated with total mortality and six factors with CRC-specific mortality. For most of the inflammatory factors the association between higher tertile levels and an increased mortality in general appeared two years after surgery.

Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. World J Gastroenterol 2017; 23(34): 6212-6219 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i34/6212.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i34.6212

INTRODUCTION
Inflammation is of importance in cancer development, and many tumours develop due to prolonged or chronic inflammation throughout their progression[1]. Carcinogenesis in colorectal cancer (CRC) is a multistep process maintained by accumulation of genetic and epigenetic aberrations in several pathways[2,3]. Also, local immunoregulation mediated by inflammatory cells, such as white blood cells, of the tumour microenvironment are involved in the release of inflammatory factors that are able to activate local immune networks to promote both the development and growth of malignant CRC cells by increasing their proliferation, survival and angiogenesis[4,5]. Inflammatory factors such as cytokines together with angiogenic factors are able to trigger the development of invasive abilities as they increase the migration and motility of tumour cells, resulting in the occurrence of metastasis[6]. Cytokines, which include chemokines and interleukins, are a broad and loose category of small proteins produced by white blood cells, stromal cells and cancer cells[7,8]. They are able to regulate the intensity and duration of the immune response by either stimulating or inhibiting the activation, proliferation and/or differentiation of various cells and are also able to regulate the secretion of antibodies and other cytokines[9]. By targeting selected cytokine networks or pathways one may be able to restrain CRC tumorigenesis or even improve the response rate in CRC tumours to chemotherapies, and there are several clinical trials that have focused on evaluating the blockade of different cytokines[6-8].

Increased levels of inflammatory factors have been associated with increased mortality in CRC patients, also in stage I which has a good oncological prognosis, but also in asymptomatic assumed healthy individuals[10-12]. The aim of this paper was to study the association of plasma levels of cytokines, chemokines and interleukins in CRC patients at the time of surgery with survival. The hypothesis is that strong inflammation at the time of surgery is associated with worse prognosis.

MATERIALS AND METHODS
Study population
This study involved analysis of plasma samples from 174 CRC patients from southeastern Sweden who had undergone surgical resections for primary colorectal adenocarcinoma between 2006-2013 at the Department of Surgery, County Hospital Ryhov, Region of Jönköping County, Jönköping, Sweden. The clinicopathological characteristics of the patients were obtained from surgical and pathological records. Follow-up was performed by consulting the medical records from all hospital departments and the primary care up to January 31, 2016. The date of an eventual cancer recurrence and the date and cause of death as related to CRC-specific mortality or not were determined from a review of the patient’s files. The study was approved by the Regional Ethical Review Board in Linköping, Linköping, Sweden, and written informed consent was obtained from each patient.
Plasma samples
Venous blood samples were collected at the time of surgery and centrifuged to separate plasma and blood cells. Plasma was stored at -80 °C until analysis. Plasma samples were available from 174 patients (69 females and 105 men), and their median age was 70 years (range 29–90). The patients’ tumours were localized in the colon (n = 105) or rectum (n = 69) and were classified as stage I (n = 24), stage II (n = 54), stage III (n = 67) and stage IV (n = 29).

Human cytokine assay
Diluted plasma (1:4) from 174 CRC patients and an eight-point standard curve were analysed for each of the 40 factors using a commercial Bio-Plex Pro™ Human Chemokine Panel 40-Plex (Bio-Rad Laboratories, Inc., CA, United States) including chemokines, cytokines and interleukins according to the manufacturer’s recommendations. Magnetic separation was performed using the Bio-Plex Pro Wash Station (Bio-Rad Laboratories). Bead fluorescence readings were taken using the Bio-Plex Manager version 6.1.0.727 (Bio-Rad Laboratories) with Low PMT (Low RP1) setting on the Bio-Plex 200 System (Bio-Rad Laboratories). The results are presented as pg/mL and grouped into tertiles defined as low, middle or high tertile.

Statistical analysis
A Shapiro-Wilk test was used to determine the normal distribution. The Pearson χ² test was used to determine differences in distribution of covariates; age, gender, localization, cancer recurrence, radical surgery, TNM stage, preoperative treatment, and adjuvant treatment between patients with CRC-specific mortality compared to survivors or deceased by other causes. An association of the inflammatory variables with TNM stage was analysed by comparing the distribution of inflammatory factors using Jonkheere Terpstra test. Magnetic separation was performed using the Bio-Plex Pro Wash Station (Bio-Rad Laboratories). Bead fluorescence readings were taken using the Bio-Plex Manager version 6.1.0.727 (Bio-Rad Laboratories) with Low PMT (Low RP1) setting on the Bio-Plex 200 System (Bio-Rad Laboratories). The results are presented as pg/mL and grouped into tertiles defined as low, middle or high tertile.

RESULTS
Clinical baseline characteristics
The clinical baseline characteristics of the total study population are presented in Table 1. Out of 174 patients, 40 died because of CRC. Thirty-five of these were stage III and IV patients. Twenty-six of the 174 patients died from other causes and 108 were still alive at the end of follow-up. Frequency of radical surgery, TNM stage and adjuvant treatment differed significantly between patients with CRC-specific mortality compared with survivors or deceased by other causes. On the other hand, age, gender, localization of the cancer and preoperative treatment did not differ between the groups. A threshold of P < 0.20 was set for the covariates used in the adjustment of statistical analyses. Age was included in the adjusted model since mortality is highly associated with increased age in general.

Associations between TNM stage and levels of inflammatory factors
Each of the inflammatory factors were tested for any eventual association with TNM stage by the Jonkheere Terpstra test. Only CCL20, CCL27, IL-8 and MIF were associated with TNM stage (Table 2).

Total mortality in relation to high tertile levels of inflammatory factors
In a univariate Cox regression analysis, the highest tertile levels of 14 factors, CCL1, CCL3, CCL15, CCL20, CX3CL1, CXCL1, CXCL10, CXCL13, IFN-γ, IL-1β, IL-2, IL-4, IL-8/CXCL8 and IL-10, were significantly associated with total mortality (Table 3). CX3CL1 had the highest hazard ratio (HR) of 3.3 with a 95%CI of 1.8–6.1, P < 0.001, for the highest tertile. Nine of the factors in the univariate analysis, CCL1, CCL15, CCL20, CX3CL1, CXCL13, IFN-γ, IL-2, IL-4 and IL-10, remained significant after adjustment of clinical covariates with P < 0.20, such as TNM stage, radical surgery, preoperative- and adjuvant treatment and age. Figure 1 shows an example of a Kaplan-Meier analysis of plasma levels of IFN-γ and an increased risk of total mortality. The Kaplan-Meier curves illustrate mortality as a function of follow-up time in relation to tertile levels.

CRC-specific mortality in relation to high levels of inflammatory factors
When investigating the CRC specific mortality among the inflammatory factors, the univariate Cox regression analysis revealed that the highest tertile levels of 8 factors, CCL1, CCL3, CCL15, CCL20, CX3CL1, CXCL16, IL-4 and IL-8/CXCL8, were significantly associated with CRC specific mortality (Table 4). CCL20 showed the highest HR of 4, CI of 1.6–10.1, P < 0.01. After adjustment for clinical covariates with P < 0.20, only 4 factors remained significant, CCL1, CCL20, CX3CL1 and IL-4. In addition, TNF-α and CCL24 became significant after this adjustment. Kaplan-Meier analysis of CRC specific mortality and tertile levels of CCL1 is shown in Figure 2.

In summary, higher tertile levels of the inflammatory factors CCL1, CCL20, CX3CL1 and IL-4 were all associated with increased risk of both total and CRC-
a commercial multiplex kit, which allow simultaneous quantification of several factors of interest, to determine whether the plasma levels of these factors were associated with CRC prognosis.

We found that high tertile levels of CCL1, CCL20, CX3CL1 and IL-4 were associated with increased CRC-specific mortality in a multivariate Cox regression analysis. We also found an increased total mortality in association of high tertile levels of CCL1, CCL15, CCL20, CX3CL1, CXCL13, IFN-γ, IL-2, IL-4 and IL-10.

Several studies have focused on higher or lower levels of some of the inflammatory factors included in our study such as CCL15, CCL20, CX3CL1, CXCL13, CXCL16, IL-4, IL-8/CXCL8, IL-10 and TNF-α by either comparing expression levels in tissue, in serum or specific mortality after Cox regression analysis when adjusted for clinical covariates. Higher tertile levels of TNF-α and CCL24 were exclusively associated with CRC-specific mortality. For most of the inflammatory factors the association between higher tertile levels and an increased mortality in general appeared two years after surgery. Twenty three inflammatory factors did not have any association with CRC-specific or total mortality when studying the follow-up time in relation to the tertile levels of these factors (Table 5).

**DISCUSSION**

In this study, we screened plasma samples from 174 CRC patients for 40 different inflammatory factors using a commercial multiplex kit, which allow simultaneous quantification of several factors of interest, to determine whether the plasma levels of these factors were associated with CRC prognosis.

We found that high tertile levels of CCL1, CCL20, CX3CL1 and IL-4 were associated with increased CRC-specific mortality in a multivariate Cox regression analysis. We also found an increased total mortality in association of high tertile levels of CCL1, CCL15, CCL20, CX3CL1, CXCL13, IFN-γ, IL-2, IL-4 and IL-10.

Several studies have focused on higher or lower levels of some of the inflammatory factors included in our study such as CCL15, CCL20, CX3CL1, CXCL13, CXCL16, IL-4, IL-8/CXCL8, IL-10 and TNF-α by either comparing expression levels in tissue, in serum or
in plasma from CRC patients and controls or among patients only\textsuperscript{[13-22]}. Also, expression levels of some of these factors have been studied in relation to survival\textsuperscript{[13-15,17,18,20-22]}. More recent studies have found an association of increased levels of inflammatory markers and increased mortality in CRC patients, but also in CRC patients stage I and in asymptomatic healthy individuals\textsuperscript{[9-12]}. Our findings of a worse prognosis in association with increased level of inflammation may therefore be a more general phenomenon and not directly related to the cancer disease. As mentioned, the local immunoregulation mediated by inflammatory cells, such as white blood cells, of the tumour microenvironment are important for the release of inflammatory factors such as cytokines, which are able to activate local immune networks to promote both the development and growth of malignant CRC cells\textsuperscript{[1,4]}. White blood cells

Table 3  Total mortality and association with highest tertile level of inflammatory factors

| Factor          | Total mortality         | Total mortality adjusted$^1$ |
|-----------------|-------------------------|------------------------------|
|                 | HR (95%CI)              | P value                      | HR (95%CI)              | P value                      |
| Age             | 1.0 (1.0-1.1)           | 0.006                        | 1.1 (1.0-1.1)           | < 0.001                     |
| TNM stage II    | 1.5 (1.0-4.0)           | 0.464                        | 1.2 (0.4-3.2)           | 0.777                        |
| TNM stage III   | 1.8 (1.7-4.8)           | 0.228                        | 2.2 (0.8-6.1)           | 0.141                        |
| TNM stage IV    | 6.8 (2.6-17.9)          | < 0.001                      | 14.6 (6.0-42.6)         | < 0.001                     |
| Radical surgery | 0.2 (0.1-0.4)           | < 0.001                      | 0.3 (0.1-0.6)           | 0.002                        |
| Preoperative treatment | 0.8 (0.1-1.5) | 0.454                        | 0.7 (0.4-1.4)           | 0.338                        |
| Adjuvant treatment | 1.1 (0.6-1.7)  | 0.842                        | 0.7 (0.4-1.3)           | 0.226                        |
| CCL1            | 3.2 (1.7-5.9)           | < 0.001                      | 2.7 (1.4-5.4)           | 0.004                        |
| CCL3            | 2.0 (1.1-3.6)           | 0.030                        | 1.2 (0.6-2.2)           | 0.605                        |
| CCL15           | 2.3 (1.2-4.3)           | 0.010                        | 1.9 (1.0-3.7)           | 0.046                        |
| CCL20           | 3.1 (1.6-6.0)           | 0.001                        | 2.2 (1.1-4.3)           | 0.021                        |
| CCL26           | 1.7 (1.0-3.0)           | 0.055                        | 1.7 (0.9-3.0)           | 0.078                        |
| CXCL1           | 3.3 (1.8-6.1)           | < 0.001                      | 2.3 (1.2-4.5)           | 0.014                        |
| CXCL10          | 1.9 (1.0-3.4)           | 0.038                        | 1.4 (0.8-2.6)           | 0.295                        |
| CXCL13          | 2.1 (1.1-4.0)           | 0.017                        | 1.3 (0.7-2.6)           | 0.387                        |
| CXCL16          | 1.8 (1.1-3.2)           | 0.033                        | 2.0 (1.0-3.7)           | 0.039                        |
| IFN-γ           | 3.1 (1.6-6.1)           | 0.001                        | 3.5 (1.6-7.5)           | 0.001                        |
| IL-1β           | 2.1 (1.2-3.8)           | 0.012                        | 1.7 (0.9-3.1)           | 0.081                        |
| IL-2            | 2.2 (1.2-4.2)           | 0.011                        | 2.7 (1.4-5.4)           | 0.005                        |
| IL-4            | 2.4 (1.2-4.6)           | 0.014                        | 2.3 (1.3-4.5)           | 0.018                        |
| IL-8/CXCL8      | 2.6 (1.4-4.6)           | 0.002                        | 1.6 (0.9-3.0)           | 0.115                        |
| TNF-α           | 2.1 (0.9-2.8)           | 0.104                        | 1.5 (0.8-2.6)           | 0.202                        |

$^1$When adjusted for age, TNM stage, radical surgery, preoperative- and adjuvant treatment.

Table 4  Colorectal cancer specific mortality and the association with highest tertile level of inflammatory factors

| Factor          | CRC specific mortality | CRC specific mortality adjusted$^1$ |
|-----------------|-------------------------|-----------------------------------|
|                 | HR (95%CI)              | P value                           | HR (95%CI)              | P value                           |
| Age             | 1.0 (1.0-1.0)           | 0.532                             | 1.1 (1.0-1.1)           | 0.006                             |
| TNM stage II    | 0.7 (0.4-1.1)           | 0.674                             | 0.5 (0.3-1.0)           | 0.444                             |
| TNM stage III   | 2.6 (0.6-11.7)          | 0.201                             | 2.7 (0.6-12.9)          | 0.209                             |
| TNM stage IV    | 15.5 (3.6-66.3)         | < 0.001                           | 27.6 (5.8-131.1)        | < 0.001                           |
| Radical surgery | 0.2 (0.1-0.5)           | 0.001                             | 0.19 (0.1-0.5)          | 0.001                             |
| Preoperative treatment | 0.5 (0.2-1.2) | 0.106                             | 0.4 (0.1-0.9)           | 0.359                             |
| Adjuvant treatment | 2.2 (1.2-4.2)          | 0.013                             | 0.9 (0.5-2.0)           | 0.947                             |
| CCL1            | 3.2 (1.4-7.0)           | 0.004                             | 2.8 (1.1-7.1)           | 0.025                             |
| CCL3            | 2.4 (1.1-5.3)           | 0.036                             | 1.2 (0.5-2.8)           | 0.653                             |
| CCL15           | 2.8 (1.3-6.3)           | 0.011                             | 2.0 (0.9-4.9)           | 0.107                             |
| CCL20           | 4.0 (1.6-10.1)          | 0.003                             | 2.7 (1.0-7.0)           | 0.046                             |
| CCL24           | 2.2 (1.0-4.8)           | 0.061                             | 2.5 (1.1-5.7)           | 0.037                             |
| CXCL1           | 3.7 (1.6-8.3)           | 0.002                             | 2.6 (1.1-6.4)           | 0.036                             |
| CXCL16          | 2.5 (1.1-5.4)           | 0.022                             | 2.0 (0.8-4.8)           | 0.138                             |
| IFN-γ           | 1.8 (0.8-3.9)           | 0.138                             | 1.7 (0.7-4.1)           | 0.253                             |
| IL-1β           | 1.9 (0.9-3.8)           | 0.090                             | 1.7 (0.8-3.6)           | 0.093                             |
| IL-4            | 2.5 (1.1-5.7)           | 0.033                             | 2.4 (1.0-5.5)           | 0.048                             |
| IL-8/CXCL8      | 3.3 (1.5-7.3)           | 0.003                             | 1.5 (0.6-3.5)           | 0.344                             |
| TNF-α           | 2.0 (0.9-4.2)           | 0.078                             | 2.3 (1.0-5.4)           | 0.047                             |

$^1$When adjusted for age, TNM stage, radical surgery, preoperative- and adjuvant treatment. CRC: Colorectal cancer.
play an important part in immunoregulation but play
dual roles. They are supposed to defeat the cancer
development by producing cytokines and activating
inflammatory signalling pathways enabling necrosis or
apoptosis of cancer cells. But the cancer itself may also
induce an immunomodulation of the white blood cells,
making them unable to produce cytokines and other
inflammatory factors. In this way, the cancer cells avoid
inflammatory recognition and are then able to continue
their development1,4.

The CX3CL1 chemokine is expressed by epithelial
cells in both CRC and normal colorectal mucosa.
Higher levels of this chemokine have been associated
with better prognosis and higher survival rate in CRC
patients, depending on anti-tumour immunity through
a higher number of attracted lymphocytes16. This is
contradictory to our findings in the univariate analysis,
which show an association between higher tertile levels
of CX3CL1 and a > 3.5-fold increased risk for CRC-
specific mortality among our CRC patients.

The CCL15 chemokine has a strong chemotactic
activity for myeloid cells such as dendritic cells,
monocytes, neutrophils and some T-lymphocytes23.
In a study by Inamoto et al23 a trend between higher
levels of CCL15 and poor survival among CRC patients
was observed. In this study we confirm that a higher
inflammatory tertile level of CCL15 is related to CRC-
specific mortality when we do not include age as a
covariate in the statistical analysis.

Expression of the CCL20 chemokine has been
demonstrated in dendritic cells, macrophages, eosino-
ophilic granulocytes and in B- and T-cell lymphocytes,
as reviewed by Schutyser et al24. In CRC, higher serum
levels of CCL20 may serve as a potential biomarker
for prognosis. It may also be useful for identification
of patients with increased risk of disease recurrence
in stage II CRC24. In the present investigation, higher
tertile levels of CCL20 in plasma is associated with a
4-fold increased risk for CRC-specific mortality in the
univariate analysis, which could be explained by a
relation to TNM stage.

IL-4 is produced by basophils, activated T-lymphocytes
and mast cells and seems to be upregulated in CRC25,26.
It has been suggested that IL-4 might be involved in
the process of supporting the tumour-initiating cells,
ensuring them to escape immune surveillance and in turn
promote CRC progression19. Our data show that the
highest tertile level of IL-4 is associated with an increased
risk of CRC specific mortality as a result of ongoing CRC
progression over time.

The CCL1 chemokine is secreted from fibroblasts27
and Th2 cells28. CCL1 has been implicated in other
types of cancer but little is known about its effects on
CRC27. The Th2-cells express the CCR8 receptor29,30,
which is activated by CCL131, and it mediates Th2 cell
recruitment to sites of inflammation23,33. In cancer,
the CCL1-CCR8 autocrine loop has been shown to have a
protective function by enabling lymphoma and T cell
leukaemia cells to avoid apoptosis in vitro34,35 and to
play a role in T cell transformation36. In this study,
higher tertile levels of this chemokine were associated
with a 2.8 fold increased risk for CRC-specific mortality
and one might speculate that the CCL1-CCR8 autocrine
loop may help CRC cells to progress their development
and spread. Due to our results CCL1 might be a new
important factor to consider in further studies regarding
its implications on CRC.

There are several limitations identified in our study
that need to be taken into consideration. First, a control
group was not included in the present work since our
focus was on survival among CRC patients, making
us unable to study differences and/or associations in
levels of the inflammatory factors among patients and
healthy individuals. However, there are already several
studies that have investigated differences in levels of
cytokines among both patients and healthy control
subjects37,38. Second, our cohort was relatively small
influencing the statistical evaluation and especially
associations with stage, which was weak due to
low power. This also makes it difficult to stratify the
patients into respect to more variables such as type
of surgery, with inflammatory complicated CRC such
as peritumorous abscess, perforation or peritonitis, or
inflammatory bowel disease. Third, it is also important
to realize that the level of inflammatory factors in
the circulation might reflect the release of factors
during cancer carcinogenesis, due to other underlying
diseases or by systemic inflammation in general. In
this study we did not have the possibility to investigate
this.

Future aspects should focus on studying these
inflammatory factors in a larger CRC patient cohort
to see if they might have the potential as biomarkers
that can be measured through a rapid, simple, non-
invasive and less costly plasma analysis enabling the
identification of CRC patients with worse prognosis.
Functional studies are needed to elucidate whether
these are causative factors for tumour progression or a
biomarker for CRC prognosis or a marker for a general
fragility.

Table 5  Inflammatory factors not associated with colorectal
cancer specific or total mortality

| Factor | Factor |
|--------|--------|
| CCL2   | CCL27  |
| CCL7   | CXCL12 |
| CCL8   | CCL15  |
| CCL11  | CXCL6  |
| CCL13  | CXCL9  |
| CCL17  | CXCL11 |
| CCL19  | CXCL12 |
| CCL21  | GM-CSF |
| CCL22  | IL-6   |
| CCL23  | IL-16  |
| CCL25  | MIF    |
| CCL26  |        |

Olsen RS et al. Circulating inflammatory factors in CRC
In summary, high tertile levels of a range of chemokines, cytokines and interleukins are associated with a worse prognosis in patients operated for CRC, both as expressed as cancer specific mortality (CCL1, CCL20, CCL24, CX3CL1, IL-4 and TNF-α) and total mortality (CCL1, CCL15, CCL20, CX3CL1, CXCL13, IFN-γ, IL-2, IL-4 and IL-10). This suggests that the observed association of a worse prognosis in CRC patients with an increased level of inflammation may not only be associated to the cancer disease but expression of a fragile host.

REFERENCES

1 Barkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]
2 Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997; 94: 2545-2550 [PMID: 9122232]
3 Jones PA, Laird PW. Cancer epigenetics come of age. Nat Genet 1999; 21: 163-167 [PMID: 9988266 DOI: 10.1038/5947]
4 Lin EF, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-740 [PMID: 11257139]
5 Gallin J, Snyderman R, Fearon DT, Haynes BF, Nathan C. Inflammation: Basic Principles and Clinical Correlates. 3rd ed. Philadelphia: Lippincott Williams Wilkins, 1999
6 Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Roundwell KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007; 110: 1396-1403 [PMID: 17674351 DOI: 10.1002/cncr.22944]
7 Angevin E, Tabernero J, Elez E, Cohen SJ, Bahloul R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. A phase I/II, multi-dose, dose-escalation study of siltuximab, an anti- interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2014; 20: 2192-2204 [PMID: 24563479 DOI: 10.1158/1078-0432.CCR-13-2200]
8 Shantha Kumaram IB, Myers EA, Herath SA, Jang JH, Njoh L, Van X, Kirchoff D, Celec V, Luchtefeld M, Whelan RL. Plasma monocyte chemotactic protein-1 remains elevated after minimally invasive colorectal cancer resection. World J Gastrointest Oncol 2014; 6: 413-419 [PMID: 25320658 DOI: 10.4251/wjgo.v6.i10.413]
9 Mansouri D, Powell AG, Park JH, McMillan DC, Horgan PG. Long-Term Follow-Up of Patients Undergoing Resection of TNM Stage I Colorectal Cancer: An Analysis of Tumour and Host Determinants of Outcome. World J Surg 2016; 40: 1485-1491 [PMID: 26920405 DOI: 10.1007/s00268-016-3443-2]
10 Watt DG, McSorley ST, Park JH, Horgan PG, McMillan DC. A Postoperative Systemic Inflammation Score Predicts Short- and Long-Term Outcomes in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg Oncol 2017; 24: 1100-1109 [PMID: 27822634 DOI: 10.1245/s10434-016-5699-4]
11 McSorley ST, Watt DG, Horgan PG, McMillan DC. Postoperative Systemic Inflammatory Response, Complication Severity, and Survival Following Surgery for Colorectal Cancer. Ann Surg Oncol 2016; 23: 2832-2840 [PMID: 27016295 DOI: 10.1245/s10434-016-5204-5]
12 Singh-Manoux A, Shipley MJ, Bell JA, Canonicco M, Elbaz A, Kivimäki M. Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. CMAJ 2017; 189: E384-E390 [PMID: 27895145 DOI: 10.1503/cmaj.160313]
13 Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, Hasagawa S, Taketo MM, Sakai Y, Kawada K. Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis. Clin Cancer Res 2016; 22: 492-501 [PMID: 26341919 DOI: 10.1158/1078-0432.CCR-15-0726]
14 Iwata T, Tanaka K, Inoue Y, Toiyama Y, Hiro J, Fujikawa H, Okugawa Y, Uchida K, Mohri Y, Kusunoki M. Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer. J Surg Oncol 2013; 107: 160-166 [PMID: 22926691 DOI: 10.1002/jso.23247]
15 Dinhberg J, Diens Kun O, Løfgren S, Hugander A, Wågström D. Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis 2007; 22: 1195-1200 [PMID: 17611763 DOI: 10.1007/s00384-007-0434-6]
16 Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005; 26: 41-47 [PMID: 15586223]
17 Qi XW, Xia SH, Yin Y, Jin LF, Pu Y, Hua D, Wu HR. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. Eur Rev Med Pharmacol Sci 2014; 18: 1916-1924 [PMID: 25010623]
18 Matsushita K, Toyama Y, Tanaka K, Saiagusa K, Hiro J, Uchida K, Inoue Y, Kusunoki M. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012; 19 Suppl 3: S518-S527 [PMID: 21845947 DOI: 10.1245/s10434-011-1993-8]
19 Volontè A, Di Tomaso T, Spinnelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Gihardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccioli C. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through
membrane-bound IL-4. J Immunol 2014; 192: 523-532 [PMID: 24277698 DOI: 10.4049/jimmunol.1301342]

20 Di Carlo G, Carvello P, Pesce S, Erreni M, Marchesi F, Todoric J, Saechi M, Montorsi M, Allavena P, Spinelli A. Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer. PLoS One 2011; 11: e0148186 [PMID: 26859579 DOI: 10.1371/journal.pone.0148186]

21 Al Obeed OA, Alkhayal KA, Al Sheikh A, Zubaidi AM, Vaali-Mohammed MA, Boushey R, Mckerrow JH, Abdulla MH. Increased expression of tumor necrosis factor-alpha is associated with advanced colorectal cancer stages. World J Gastroenterol 2014; 20: 18390-18396 [PMID: 25561807 DOI: 10.3748/wjg.v20.i48.18390]

22 Stanilov N, Miteva L, Dobrea Z, Stanilova S. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha. Biotechnol Biotechnol Equip 2014; 28: 911-917 [PMID: 26019577 DOI: 10.13102/bbe.2014.950047]

23 Forssmann U, Mägert HJ, Adermann K, Escher SE, Forssmann WG. Hemofiltrate CC chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15. J Leukoc Biol 2001; 70: 357-366 [PMID: 11527964]

24 Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409-426 [PMID: 12948524]

25 Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300: 1527-1528 [PMID: 12791978 DOI: 10.1126/science.1085458]

26 Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zazinidouhou F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964 [PMID: 17008531 DOI: 10.1126/science.1129139]

27 Yeh CR, Hsu I, Song W, Chang H, Miyamoto H, Xiao QG, Li L, Yeh S. Fibroblast ERα promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. Am J Cancer Res 2015; 5: 1146-1157 [PMID: 26045993]

28 Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F, D’Ambrosio D, O’Garra A, Robinson D, Rocchi M, Santoni A, Zlotnik A, Napolitano M. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998; 161: 547-551 [PMID: 9670926]

29 Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J. Chemokine receptor expression identifies Pre-Th helper (Th1), Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med 2004; 200: 725-735 [PMID: 15381728 DOI: 10.1084/jem.20040774]

30 Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187: 875-883 [PMID: 9500790]

31 Roos RS, Loetscher M, Legler DF, Clark-Lewis I, Baggioili M, Moser B. Identification of CCR8, the receptor for the human chemokine I-309. J Biol Chem 1997; 272: 17251-17254 [PMID: 9211859]

32 Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, Kunkel SL, Kung T, Wiekowski MT, Hedrick JA, Cook DN, Zingoni A, Narula SK, Zlotnik A, Barat FJ, O’Garra A, Napolitano M, Lira SA. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2001; 193: 573-584 [PMID: 11238588]

33 Islam SA, Chang DS, Colvin RA, Byrne MH, McCully ML, Moser B, Lira S, Charo IF, Luster AD. Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nat Immunol 2011; 12: 167-177 [PMID: 21217759 DOI: 10.1038/ni.1984]

34 Van Snick J, Houssiau F, Proost P, Van Damme J, Renaud JC. I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis. J Immunol 1996; 157: 2570-2576 [PMID: 8805659]

35 Ruckes T, Saul D, Van Snick J, Hermine O, Grassmann R. Autoimmune antipapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood 2001; 98: 1150-1159 [PMID: 11493464]

36 Tangüney G, Van Snick J, Fickenscher H. Autoimmune stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/309. Oncogene 2004; 23: 8475-8485 [PMID: 15378023 DOI: 10.1038/sj.onc.1207903]

37 Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M, Schrezenmeier H, Wolf AM, Knippschild U. Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls. BMC Cancer 2012; 12: 545 [PMID: 23173608 DOI: 10.1186/1471-2407-12-545]

38 Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, Knowles M, Gee N, Nielsen HJ, Bründer N, Christensen UJ, Fredriksen S, Stenvang J, Assarsson E. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomat individuals. J Transl Med 2013; 11: 253 [PMID: 24107468 DOI: 10.1186/1479-5876-11-253]

P-Reviewer: Hua D, Ju SQ, Sokolov M
S-Editor: Gong ZM
L-Editor: A
E-Editor: Zhang FF
